What is Intuitive Surgical's revenue performance for the quarter and year-to-date?

Intuitive Surgical reported substantial revenue growth. For the third quarter ended September 30, 2002, revenue increased by 57% to $17.1 million compared to the same period in 2001. For the first nine months of 2002, revenue grew by 43% to $50.9 million compared to the prior year. This growth was primarily attributed to an increase in da Vinci Surgical System placements and a significant rise in recurring revenue from instruments, accessories, and service.

Is the company profitable, and what is its net loss trend?

No, Intuitive Surgical reported a net loss for the quarter and year-to-date periods. The net loss for the third quarter of 2002 was $6.5 million ($0.18 per share), an increase from the $4.8 million loss ($0.13 per share) in the third quarter of 2001. For the nine months ended September 30, 2002, the net loss was $15.8 million ($0.43 per share), compared to a net loss of $12.4 million ($0.35 per share) for the same period in 2001. The increased losses reflect higher operating expenses, particularly in R&D and SG&A, which include significant investments and litigation costs.

What is the company's financial position and liquidity outlook?

As of September 30, 2002, Intuitive Surgical had $18.3 million in cash and cash equivalents and $30.2 million in short-term investments, providing a total of approximately $48.5 million in liquid assets. Working capital stood at $54.2 million. Management believes its current cash and investment balances, along with anticipated revenues, are sufficient to fund operations at least through 2003. However, the company may need to seek additional financing in the future, which could involve issuing equity or debt securities, potentially leading to dilution for existing stockholders.

What are the major risks or challenges facing Intuitive Surgical?

Intuitive Surgical faces several significant risks. A primary concern is the ongoing intellectual property litigation with Computer Motion, Inc. and Brookhill-Wilk 1, LLC, which could lead to substantial damages, injunctions preventing product sales, or require costly licensing agreements. The company also operates in a competitive market for surgical technologies, faces long and variable sales cycles for its high-value capital equipment, and relies on market acceptance of its innovative procedures. Furthermore, substantial ongoing investment in R&D and SG&A, including litigation costs, contributes to ongoing net losses. Management also highlights dependence on key personnel and potential manufacturing challenges.

ISRG 10-Q Quarterly Report Q3 FY2002 — Revenue, Net Income, EPS

Summary

Intuitive Surgical Inc. (ISRG) reported its third-quarter and year-to-date results for the period ending September 30, 2002. The company continues to experience significant sales growth, with a 57% increase in revenue for the third quarter and a 43% increase for the first nine months compared to the prior year. This growth is driven by higher placements of the da Vinci Surgical System and a substantial increase in recurring revenue from instruments, accessories, and service. Despite the top-line growth, the company reported a net loss for both the quarter ($6.5 million) and the year-to-date period ($15.8 million), reflecting continued investment in research and development and selling, general, and administrative expenses, including litigation costs. The company's gross profit margin improved to 51% from 47% in the prior year, attributed to higher average selling prices for the da Vinci system and manufacturing efficiencies. Financially, Intuitive Surgical ended the period with $18.3 million in cash and cash equivalents and $30.2 million in short-term investments, totaling approximately $48.5 million in liquid assets. The company's working capital decreased to $54.2 million from $67.9 million at the end of 2001, primarily due to the net loss and investments in fixed assets. Management expects current cash and investments to fund operations through 2003, but anticipates potential needs for additional financing thereafter. A significant ongoing risk highlighted is the intellectual property litigation with Computer Motion and Brookhill-Wilk 1, LLC, which could materially impact the company's competitive position and financial results.

Key Highlights

1Revenue increased by 57% in Q3 2002 to $17.1 million and by 43% for the first nine months of 2002 to $50.9 million, driven by da Vinci Surgical System placements and recurring revenue.
2Recurring revenue (instruments, accessories, and service) more than doubled, increasing by 135% in Q3 and 122% for the first nine months, indicating growing installed base utilization.
3Gross profit margin improved to 51% in Q3 and year-to-date 2002, up from 47% in the prior year, due to higher average selling prices and manufacturing efficiencies.
4Net loss widened to $6.5 million in Q3 2002 ($0.18 per share) and to $15.8 million ($0.43 per share) for the first nine months, compared to losses of $4.8 million and $12.4 million, respectively, in the prior year.
5Research and Development (R&D) expenses increased by 11% in Q3 and 27% year-to-date, reflecting ongoing investment in product development.
6Selling, General, and Administrative (SG&A) expenses increased significantly (57% in Q3, 38% year-to-date), impacted by headcount additions and litigation costs.
7The company held $18.3 million in cash and cash equivalents and $30.2 million in short-term investments as of September 30, 2002, with management expecting these resources to fund operations through 2003.
8Significant ongoing litigation with Computer Motion Inc. and Brookhill-Wilk 1, LLC poses a material risk, potentially impacting competitive position, sales, and financial results.

INTUITIVE SURGICAL INC Quarterly Report for Q3 Ended Sep 30, 2002

Summary

Key Highlights

Frequently Asked Questions